Paras Biopharmaceuticals Finland Oy Paras Finland (Europe) is a fast growing biopharmaceutical technology development company which has successfully developed the proprietary Diabrid Platform Technology for the high level expression of biosimilars and long therapeutic peptides in specially designed genetically stable clones. Paras Biopharmaceuticals Finland Oy is specialized in design, development and optimization of manufacturing technologies for therapeutic peptides and soon to be off patent biologics. The company is building a robust portfolio of proprietary technologies and has developed extensive intellectual property. Paras has developed multiple novel technologies, 1. Diabrid® Technology 2. NobleCleav®Technologies 3. Biomultifold® Technology 4. Cytoplasmic Protein Folding Technologies Key Highlights of Paras Collaboration • Paras Biopharmaceuticals Finland ( Europe) has Advanced Bio-technologies for Production of Biologics APIs – Mainly Analog Insulins, Osteoporosis (Teriparatide), and Rheumatoid Arthritis and Oncology products. • Paras Biopharmaceuticals Finland has a World Class cGMP facility in Finland with Commercial Approval for Production of Biologics APIs.